Cargando…

A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies

The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoe...

Descripción completa

Detalles Bibliográficos
Autores principales: Härkönen, Jouni, Pölönen, Petri, Deen, Ashik Jawahar, Selvarajan, Ilakya, Teppo, Hanna-Riikka, Dimova, Elitsa Y., Kietzmann, Thomas, Ahtiainen, Maarit, Väyrynen, Juha P., Väyrynen, Sara A., Elomaa, Hanna, Tynkkynen, Niko, Eklund, Tiia, Kuopio, Teijo, Talvitie, Eva-Maria, Taimen, Pekka, Kallajoki, Markku, Kaikkonen, Minna U., Heinäniemi, Merja, Levonen, Anna-Liisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011429/
https://www.ncbi.nlm.nih.gov/pubmed/36867945
http://dx.doi.org/10.1016/j.redox.2023.102644
_version_ 1784906390895067136
author Härkönen, Jouni
Pölönen, Petri
Deen, Ashik Jawahar
Selvarajan, Ilakya
Teppo, Hanna-Riikka
Dimova, Elitsa Y.
Kietzmann, Thomas
Ahtiainen, Maarit
Väyrynen, Juha P.
Väyrynen, Sara A.
Elomaa, Hanna
Tynkkynen, Niko
Eklund, Tiia
Kuopio, Teijo
Talvitie, Eva-Maria
Taimen, Pekka
Kallajoki, Markku
Kaikkonen, Minna U.
Heinäniemi, Merja
Levonen, Anna-Liisa
author_facet Härkönen, Jouni
Pölönen, Petri
Deen, Ashik Jawahar
Selvarajan, Ilakya
Teppo, Hanna-Riikka
Dimova, Elitsa Y.
Kietzmann, Thomas
Ahtiainen, Maarit
Väyrynen, Juha P.
Väyrynen, Sara A.
Elomaa, Hanna
Tynkkynen, Niko
Eklund, Tiia
Kuopio, Teijo
Talvitie, Eva-Maria
Taimen, Pekka
Kallajoki, Markku
Kaikkonen, Minna U.
Heinäniemi, Merja
Levonen, Anna-Liisa
author_sort Härkönen, Jouni
collection PubMed
description The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T cell and macrophage infiltration in squamous malignancies of the lung, head and neck area, cervix and esophagus. Squamous NRF2 overactive tumors comprise a molecular phenotype with SOX2/TP63 amplification, TP53 mutation and CDKN2A loss. These immune cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1 and PD-L1. Based on our functional genomics analyses, these genes represent candidate NRF2 targets, suggesting direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. In addition, we discovered that the negative relationship of NRF2 and immune cells are explained by stromal populations of lung squamous cell carcinoma, and this effect spans multiple squamous malignancies based on our molecular subtyping and deconvolution data.
format Online
Article
Text
id pubmed-10011429
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100114292023-03-15 A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies Härkönen, Jouni Pölönen, Petri Deen, Ashik Jawahar Selvarajan, Ilakya Teppo, Hanna-Riikka Dimova, Elitsa Y. Kietzmann, Thomas Ahtiainen, Maarit Väyrynen, Juha P. Väyrynen, Sara A. Elomaa, Hanna Tynkkynen, Niko Eklund, Tiia Kuopio, Teijo Talvitie, Eva-Maria Taimen, Pekka Kallajoki, Markku Kaikkonen, Minna U. Heinäniemi, Merja Levonen, Anna-Liisa Redox Biol Research Paper The NRF2 pathway is frequently activated in various cancer types, yet a comprehensive analysis of its effects across different malignancies is currently lacking. We developed a NRF2 activity metric and utilized it to conduct a pan-cancer analysis of oncogenic NRF2 signaling. We identified an immunoevasive phenotype where high NRF2 activity is associated with low interferon-gamma (IFNγ), HLA-I expression and T cell and macrophage infiltration in squamous malignancies of the lung, head and neck area, cervix and esophagus. Squamous NRF2 overactive tumors comprise a molecular phenotype with SOX2/TP63 amplification, TP53 mutation and CDKN2A loss. These immune cold NRF2 hyperactive diseases are associated with upregulation of immunomodulatory NAMPT, WNT5A, SPP1, SLC7A11, SLC2A1 and PD-L1. Based on our functional genomics analyses, these genes represent candidate NRF2 targets, suggesting direct modulation of the tumor immune milieu. Single-cell mRNA data shows that cancer cells of this subtype exhibit decreased expression of IFNγ responsive ligands, and increased expression of immunosuppressive ligands NAMPT, SPP1 and WNT5A that mediate signaling in intercellular crosstalk. In addition, we discovered that the negative relationship of NRF2 and immune cells are explained by stromal populations of lung squamous cell carcinoma, and this effect spans multiple squamous malignancies based on our molecular subtyping and deconvolution data. Elsevier 2023-02-27 /pmc/articles/PMC10011429/ /pubmed/36867945 http://dx.doi.org/10.1016/j.redox.2023.102644 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Härkönen, Jouni
Pölönen, Petri
Deen, Ashik Jawahar
Selvarajan, Ilakya
Teppo, Hanna-Riikka
Dimova, Elitsa Y.
Kietzmann, Thomas
Ahtiainen, Maarit
Väyrynen, Juha P.
Väyrynen, Sara A.
Elomaa, Hanna
Tynkkynen, Niko
Eklund, Tiia
Kuopio, Teijo
Talvitie, Eva-Maria
Taimen, Pekka
Kallajoki, Markku
Kaikkonen, Minna U.
Heinäniemi, Merja
Levonen, Anna-Liisa
A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
title A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
title_full A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
title_fullStr A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
title_full_unstemmed A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
title_short A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies
title_sort pan-cancer analysis shows immunoevasive characteristics in nrf2 hyperactive squamous malignancies
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011429/
https://www.ncbi.nlm.nih.gov/pubmed/36867945
http://dx.doi.org/10.1016/j.redox.2023.102644
work_keys_str_mv AT harkonenjouni apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT polonenpetri apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT deenashikjawahar apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT selvarajanilakya apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT teppohannariikka apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT dimovaelitsay apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT kietzmannthomas apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT ahtiainenmaarit apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT vayrynenjuhap apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT vayrynensaraa apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT elomaahanna apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT tynkkynenniko apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT eklundtiia apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT kuopioteijo apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT talvitieevamaria apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT taimenpekka apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT kallajokimarkku apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT kaikkonenminnau apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT heinaniemimerja apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT levonenannaliisa apancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT harkonenjouni pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT polonenpetri pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT deenashikjawahar pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT selvarajanilakya pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT teppohannariikka pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT dimovaelitsay pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT kietzmannthomas pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT ahtiainenmaarit pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT vayrynenjuhap pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT vayrynensaraa pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT elomaahanna pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT tynkkynenniko pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT eklundtiia pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT kuopioteijo pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT talvitieevamaria pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT taimenpekka pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT kallajokimarkku pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT kaikkonenminnau pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT heinaniemimerja pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies
AT levonenannaliisa pancanceranalysisshowsimmunoevasivecharacteristicsinnrf2hyperactivesquamousmalignancies